Compare RWAY & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RWAY | IPHA |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.3M | 189.5M |
| IPO Year | N/A | N/A |
| Metric | RWAY | IPHA |
|---|---|---|
| Price | $5.45 | $1.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $9.50 | $5.75 |
| AVG Volume (30 Days) | ★ 646.1K | 6.3K |
| Earning Date | 05-07-2026 | 03-26-2026 |
| Dividend Yield | ★ 21.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.26 | $180.36 |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | $5.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.19 | $1.18 |
| 52 Week High | $11.20 | $2.63 |
| Indicator | RWAY | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.